Pharmaceutical regulatory filing citing a Nature paper — Arbutus Biopharma, 2015-04-22
Arbutus BiopharmaArbutus BiopharmaNASDAQ ABUS
Filings SEC · Quote Yahoo cited a paper published in Nature in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the way it wrote the paper and the scope the paper actually showed in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Arbutus Biopharma on 2015-04-22 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Nature in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
The paper is titled, "Lipid Nanoparticle siRNA Treatment of Ebola Virus Makona-infected Nonhuman Primates," (Thi et al., Nature April 22, 2015, doi:10.1038/nature14442 ) . Tekmira, along with its collaborators at the University of Texas Medical Branch at Galveston, USA, jointly conducted a preclinical study demonstrating 100% survival of nonhuman primates infected with the West Africa Makona strain of Ebola virus, previously referred to as the Guinea strain.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the company's entire claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has only read the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract ends here.
The paper's title is Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates and it was published in Nature on 2015-04-22. The authors' affiliations are Arbutus Biopharma (Canada) · The University of Texas Medical Branch at Galveston. The summary at the beginning of a paper is called abstract. This article has only read up to this point. The paragraph was rewritten by a person after filtering a draft written by a machine through numerical comparison, so it is of a different grade than a full reading of the paper.
The abstract of this paper is not publicly available, so it cannot be summarized. What can be understood from the title is that it is an animal experiment in which siRNA encapsulated in lipid nanoparticles was administered to monkeys infected with the Makona strain of the Ebola virus, which was prevalent in West Africa in 2014. It is not the result of human patients.
What the abstract does not answer remains in the full text and appendices. This article, which has not gone beyond that, leaves the blanks as they are. Readers should determine for themselves which sentence in the abstract corresponds to the part cited by the company by comparing the two citations above.
One month later, the stock price was within the lower quartile of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In terms of the calendar, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −3.8% | The extent to which the stock had already moved before the filing |
| On the day of the filing | −0.9% | Disclosure date or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | −11.8% | One week |
| Accumulated over +1 to +20 trading days | −24.8% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed in percentiles. The one-month excess return of -24.8% in this case is within the bottom quarter, at the 18% position from the bottom among 142 cases in the sample.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −24.8% |
Half of the sample falls between the two middle marks in the table. Check the table to see whether this case falls inside or outside that range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules to apply to future cases.
After the regulatory filing, the company issued this document
After the filing date, the company submitted three 8-K filings. I will list only the item numbers. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. To learn what exactly happened, read the original text through each link.
- 2015-04-23 8-K Item 8.01,9.01 — Other Events · Financial Statements · Exhibits
- 2015-05-01 8-K Item 8.01,9.01 — Other Events · Financial Statements · Exhibits
- 2015-05-06 8-K Item 2.02,9.01 — Earnings Announcement · Financial Statements · Exhibits
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper reviewed what, by what method, and to what extent. How many times the paper cited by the company was cited afterward can be verified again through the citation count on OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K filing cites the same paper again.
Glossary
- 8-K
- A Form 8-K is a report that a publicly traded company in the United States files with the Securities and Exchange Commission to inform shareholders of material events. The type of event is indicated by a specific item number, such as earnings, contracts, or executive changes. All events discussed in this article are sourced from this document.
- Excess return
- The portion of a stock's return that remains after subtracting the overall market return. It is used to isolate the movement specific to the company, excluding the general market trend.
- Trading day
- A count of days when the stock market is open. Weekends and holidays are excluded, so 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- An abstract is placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details or limitations of the methods.